StevenRGoldsmithMD
Cardiology • Minneapolis, MNAdult Congenital Heart Disease
Professor, Medicine, University of Minnesota Medical School, Minneapolis
Dr. Goldsmith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Hennepin County Medical Center
701 Park Avenue
Minneapolis, MN 55415Phone+1 612-873-2875- Is this information wrong?
Education & Training
University of MinnesotaFellowship, Cardiovascular Disease, 1978 - 1981
Ohio State University HospitalResidency, Internal Medicine, 1975 - 1978- Ohio State University College of MedicineClass of 1975
Certifications & Licensure
MN State Medical License 1978 - 2024
OH State Medical License 1976 - 1979- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure Start of enrollment: 2009 Jul 01
- Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels Start of enrollment: 2010 May 01
- Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study Start of enrollment: 2010 Aug 01
Publications & Presentations
PubMed
- 7 citationsA First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients.Peter Winkle, Steven Goldsmith, Michael J Koren, Serge Lepage, Jennifer Hellawell, Ashit Trivedi, Kate Tsirtsonis, Siddique A Abbasi, Allegra Kaufman, Richard Troughto...> ;Cardiovascular Drugs and Therapy. 2023 Aug 1
- 13 citationsDual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.Steven R. Goldsmith, Daniel Burkhoff, Finn Gustafsson, Adriaan A. Voors, Faiez Zannad, Peter Kolkhof, Gerald Staedtler, Pablo Colorado, Wilfried Dinh, James E. Udelson> ;Journal of Cardiac Failure. 2021 Feb 1
- 11 citationsVasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials:Jonathan Urbach, Steven R. Goldsmith> ;Therapeutic Advances in Cardiovascular Disease. 2021 Jan 13
- Join now to see all
Authored Content
- Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients with Heart Failure?January 2018
- Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients with Heart Failure?January 2018
Grant Support
- The Minnesota Heart Failure Consortium: A Regional Clinical CenterNational Heart, Lung, And Blood Institute2006–2011
- Nhlbi Clinical Investigator Award ProgramNational Heart, Lung, And Blood Institute1985
Professional Memberships
- Member
Hospital Affiliations
Hennepin HealthcareMinneapolis, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
